ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology Holdings Inc. (Nasdaq: ALXO) has announced an investor conference call and webcast scheduled for July 31, 2024, at 4:30 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ALX Oncology Holdings Inc. (Nasdaq: ALXO) has announced an investor conference call and webcast scheduled for July 31, 2024, at 4:30 PM EDT. The purpose of this event is to share topline data results from the Phase 2 ASPEN-06 clinical trial of evorpacept, their investigational therapy for advanced HER2-positive gastric cancer. Evorpacept is designed to block the CD47 immune checkpoint pathway.
Investors and interested parties can access the live conference call by dialing (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (international) with Conference ID 9637001. A live and archived webcast of the call, along with a slide presentation, will be available on the company's website in the News & Events section.
Positive
- ALX Oncology is ready to present topline data from a Phase 2 clinical trial
- The trial focuses on evorpacept for advanced HER2-positive gastric cancer, a significant market
- The company is providing multiple access options for investors to join the call and webcast
Negative
- None.
Details
News Market Reaction – ALXO
The recorded move for ALXO in the trading session of this news was -11.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Conference Call and Webcast Today at 4:30 PM EDT
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.
To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live and archived webcast of the conference call, please visit the News & Events section (see “Events") of the Company’s website at www.alxoncology.com, where a slide presentation will be referenced during the event.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.